Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Opana ER Pulled from U.S. Market

Michele B. Kaufman, PharmD, BCGP  |  July 11, 2017

Endo Pharmaceuticals will work with the FDA to coordinate the organized removal of Opana ER from the U.S. market.

Filed under:AnalgesicsDrug Updates Tagged with:Drug SafetyOpana ERopioidOpioid abuse

Vitamin D May Improve Outcomes for Patients with Early RA

Lara C. Pullen, PhD  |  July 10, 2017

A recent study examined the differences in T helper cell subtypes and osteoclast precursors between patients with early RA and healthy controls. Researchers found that standard treatment combined with a single dose of cholecalcipherol may better improve the general health of patients…

Filed under:ConditionsRheumatoid Arthritis Tagged with:early arthritisRheumatoid Arthritis (RA)Vitamin D

Rituximab for Fatigue & Oral Dryness in Primary Sjögren’s Syndrome

Arthritis & Rheumatology  |  June 28, 2017

These researchers investigated whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjögren’s syndrome (SS). The multicenter, randomized, double-blind, placebo-controlled, parallel-group trial included a health economic analysis. There were no significant improvements in any outcome measure with rituximab except for unstimulated salivary flow. The study concludes that rituximab is neither clinically effective nor cost effective in this patient population…

Filed under:ConditionsDrug UpdatesResearch RheumSjögren’s Disease Tagged with:Arthritis & Rheumatologyoral healthResearchrituximabSjogren's

Adenosine Treatment Promotes Cartilage Homeostasis

Lara C. Pullen, PhD  |  June 26, 2017

A recent study in mice examined the role of adenosine A2A receptors in joint health. Researchers specifically found that as extracellular levels of adenosine fall, individuals may become at risk for osteoarthritis…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Adenosinecartilagechondrocyte homeostasisosteoarthritis (OA)

Missouri Sues Opioid Manufacturers, Joining Two other U.S. States

Nate Raymond  |  June 21, 2017

(Reuters)—Missouri on Wednesday became the third U.S. state to accuse major drug manufacturers of fraudulently misrepresenting the risks of opioid painkillers now at the center of a national addiction epidemic. Missouri Attorney General Josh Hawley said his office filed a lawsuit in a state court in St. Louis against Purdue Pharma LP, Johnson and Johnson…

Filed under:Drug UpdatesPractice SupportProfessional Topics Tagged with:Endo International PlcJohnson and JohnsonMissouri lawsuitnational addiction epidemicOpioid manufacturersopioid painkillersPurdue Pharma LP

U.S. Senators Worry about Rush over Healthcare Bill ahead of Release

Susan Cornwell  |  June 21, 2017

WASHINGTON (Reuters)—U.S. senators expressed concern on Wednesday about a plan to overhaul the U.S. healthcare system, fearing a rush to consider the major legislation as Republican leaders prepare to unveil it. The healthcare bill will be released to the Republican Senate Conference on Thursday at 9:30 a.m. EDT (1330 GMT) and posted online, Senators John…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Affordable Care Act (ACA)healthcare billObamacare repealU.S. healthcare system

The Walk from the Waiting Room

Carina Stanton  |  June 16, 2017

For a rheumatology practice, rooming time can be leveraged to improve efficiency and patient care. Christie Bartels, MD, MS, and colleagues have studied this time frame and developed data-based tips and tools to decrease variation among staff and streamline practices…

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:efficiencypatient carePractice Managementpractice performancerheumatology practice

FDA Responds to New Drug Application for Baricitinib

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2017

Oxycodone Tablets Submitted to FDA Filings for oxycodone tablets (Oxaydo) in both 10 and 15 mg doses have been accepted by the U.S. Food and Drug Administration (FDA).1 The submission is based on a pharmacokinetic study demonstrating bioequivalence to the reference drug, oxycodone hydrochloride (Roxicodone) tablets at a 15 mg dose. The product is an…

Filed under:AnalgesicsConditionsDrug Updates Tagged with:analgesicApprovalsbaricitinibDisease-modifying antirheumatic drugs (DMARDs)drugFDAopioidOxycodonePsoriatic ArthritisQualityRARheumatoid arthritisSafetysecukinumabupdate

International Task Force Recommends Intra-articular Hyaluronic Acid for Knee OA

Kathy Holliman  |  June 15, 2017

An international task force convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) recommends systematic repeated intra-articular hyaluronic acid (HA) injections as second-line treatment for patients with knee osteoarthritis (OA). This is the first time a group of experts has made this recommendation, which is directed toward treatment of…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:ClinicalEuropean Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritisguidelinehyaluronic acidjointkneeOAOsteoarthritisoutcomepatient carerecommendationrheumatologistrheumatologyTreatment

U.S. State Attorneys General Probe Opioid Drug Companies

Nate Raymond  |  June 15, 2017

(Reuters)—A bipartisan group of state attorneys general announced on Thursday that they are jointly investigating the marketing and sales practices of drug companies that manufacture opioid painkillers at the center of a national addiction epidemic. Attorneys general from states including Massachusetts, Texas, Illinois and Pennsylvania announced the investigation two weeks after Ohio Attorney General Mike…

Filed under:Legal UpdatesProfessional Topics Tagged with:Allergan Plc.Endo International PlcJohnson and Johnsonnational addiction epidemicopioid drug companiesOpioid probePurdue Pharma LPTeva Pharmaceutical Industries Ltd’s Cephalon

  • « Previous Page
  • 1
  • …
  • 135
  • 136
  • 137
  • 138
  • 139
  • …
  • 243
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences